Arcadia Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Arcadia Biosciences, Inc.'s yearly results (2022–2025), compared with Consumer Defensive companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 11.7 times its market value (net cash). Higher than 98% of Consumer Defensive companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 97% of Consumer Defensive companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 96% of Consumer Defensive companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$4For every $100 of sales, $4 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier.
Less money tied up than 73% of Consumer Defensive companies in United States.
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 57% of Consumer Defensive companies in United States.
Growth Efficiency Ratio
—Sales fell 35%
Sales fell 35% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-35% / -77%In 3 years sales changed by -35% while total assets changed by -77%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
11.7× cashCash, after subtracting all debt, is 11.7 times its market value (net cash).
Higher than 98% of Consumer Defensive companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 96% of Consumer Defensive companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 97% of Consumer Defensive companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Arcadia Biosciences, Inc. made a loss over the last year. Arcadia Biosciences, Inc. owes $0.89 for every $1 it owns. Arcadia Biosciences, Inc. made a loss in each of the last two years.
Compared with Consumer Defensive companies in United States · latest annual results Dec 2025.
P/E ratio
LossArcadia Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.62The share price is 0.62 times Arcadia Biosciences, Inc.'s book value per share, lower than 85% of Consumer Defensive companies in United States.
Market cap
$0 MThe total market value of all of Arcadia Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than almost all Consumer Defensive companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$1 MWhat Arcadia Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.26Net worth divided by the number of shares. The share price of $0.16 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-430.9%Arcadia Biosciences, Inc. lost 430.9% of its shareholders' money over the last year, lower than 98% of Consumer Defensive companies in United States.
Owes vs Owns
0.89×Arcadia Biosciences, Inc. owes $0.89 for every $1 it owns (high), higher than 85% of Consumer Defensive companies in United States.
Dividend yield
NoneArcadia Biosciences, Inc. does not currently pay a dividend.
Revenue growth
-4%Revenue fell 4% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Profit growth
LossArcadia Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-48.1%Arcadia Biosciences, Inc. lost $48 for every $100 of revenue.
Cash vs debt
Net cashArcadia Biosciences, Inc. held $5 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Arcadia Biosciences, Inc.: $0 M ÷ $1 M (30 Jun 2026) = 0.6.
What is Arcadia Biosciences, Inc.'s return on equity?
Arcadia Biosciences, Inc. lost 430.9% of its shareholders' money over the last year, lower than 98% of Consumer Defensive companies in United States.
How much does Arcadia Biosciences, Inc. owe compared with what it owns?
Arcadia Biosciences, Inc. owes $0.89 for every $1 it owns (high), higher than 85% of Consumer Defensive companies in United States.
Does Arcadia Biosciences, Inc. pay a dividend?
No. Arcadia Biosciences, Inc. does not currently pay a dividend.
Is Arcadia Biosciences, Inc.'s revenue growing?
Revenue fell 4% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.